Prakash Raman
Vermogen: 94 582 $ op 31-08-2026
Vermogen: 94 582 $ op 31-08-2026
Dr. Prakash Raman is an Independent Director at Olema Pharmaceuticals, Inc., a Chief Executive Officer at Indupro, an Independent Director at Black Diamond Therapeutics, Inc., a Chief Executive Officer & Director at InduPro, Inc. and a President, Chief Executive Officer & Director at Ribon Therapeutics, Inc. He is on the Board of Directors at Olema Pharmaceuticals, Inc., Black Diamond Therapeutics, Inc., InduPro, Inc. and Ribon Therapeutics, Inc. Dr. Raman was previously employed as a VP & Global Head-NIBR Business Development by Novartis Institutes for Biomedical Research, Inc. and a Head-Project Management by AstraZeneca PLC.
He also served on the board at KSQ Therapeutics, Inc. and NAYA Therapeutics, Inc. He received his undergraduate degree from Indian Institute of Technology Bombay, a graduate degree from Indian Institute of Technology Bombay and a doctorate degree from the University of Wisconsin-Madison.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 26-06-2026 | 45.039 ( 0,08% ) | 94 582 $ | 31-08-2026 | |
| 18-06-2026 | 0 ( -.--% ) | - $ | 31-08-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Directeur/Bestuurslid | 10-04-2024 |
| OLEMA PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 28-04-2026 |
Ribon Therapeutics, Inc.
Ribon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops cacner therapies | Algemeen Directeur | 17-02-2022 |
Indupro | Algemeen Directeur | 13-06-2024 |
InduPro, Inc.
InduPro, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that specializes in protein therapeutics and cell-surface platform technologies | Algemeen Directeur | 01-04-2024 |
| Bedrijven | Functie | Einde |
|---|---|---|
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | 01-10-2019 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01-11-2012 |
KSQ Therapeutics, Inc.
KSQ Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops therapeutics for cancer | Algemeen Directeur | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 9 |
|---|---|
AstraZeneca PLC
AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Indian Institute of Technology Bombay
Indian Institute of Technology Bombay Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ribon Therapeutics, Inc.
Ribon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops cacner therapies | Health Technology |
KSQ Therapeutics, Inc.
KSQ Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops therapeutics for cancer | Health Technology |
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for the treatment & prevention of estrogen receptor positive breast cancer | Health Technology |
Indupro | |
InduPro, Inc.
InduPro, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that specializes in protein therapeutics and cell-surface platform technologies | Commercial Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau